GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (FRA:20D0) » Definitions » Shiller PE Ratio

Cidara Therapeutics (FRA:20D0) Shiller PE Ratio : (As of Dec. 15, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cidara Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Cidara Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Shiller PE Ratio Chart

Cidara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cidara Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cidara Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Cidara Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Shiller PE Ratio falls into.



Cidara Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cidara Therapeutics's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Cidara Therapeutics's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-2.207/133.0289*133.0289
=-2.207

Current CPI (Sep. 2024) = 133.0289.

Cidara Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 -5.940 99.070 -7.976
201503 -9.808 99.621 -13.097
201506 -10.514 100.684 -13.892
201509 -11.939 100.392 -15.820
201512 -13.219 99.792 -17.622
201603 -12.752 100.470 -16.884
201606 -15.130 101.688 -19.793
201609 -15.682 101.861 -20.480
201612 -16.685 101.863 -21.790
201703 -14.960 102.862 -19.347
201706 -17.622 103.349 -22.683
201709 -12.249 104.136 -15.648
201712 -11.661 104.011 -14.914
201803 -12.976 105.290 -16.395
201806 -19.346 106.317 -24.207
201809 -8.399 106.507 -10.491
201812 -7.735 105.998 -9.708
201903 -10.266 107.251 -12.734
201906 -8.319 108.070 -10.240
201909 1.453 108.329 1.784
201912 -7.560 108.420 -9.276
202003 -8.326 108.902 -10.171
202006 -7.992 108.767 -9.775
202009 -6.962 109.815 -8.434
202012 -8.056 109.897 -9.752
202103 -6.552 111.754 -7.799
202106 2.988 114.631 3.468
202109 -6.290 115.734 -7.230
202112 -4.602 117.630 -5.204
202203 -4.903 121.301 -5.377
202206 -3.595 125.017 -3.825
202209 3.434 125.227 3.648
202212 -3.587 125.222 -3.811
202303 0.560 127.348 0.585
202306 -2.787 128.729 -2.880
202309 -1.893 129.860 -1.939
202312 -0.587 129.419 -0.603
202403 -2.098 131.776 -2.118
202406 -18.571 132.554 -18.638
202409 -2.207 133.029 -2.207

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cidara Therapeutics  (FRA:20D0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cidara Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics Business Description

Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Cidara Therapeutics Headlines

No Headlines